Pfizer beats revenue estimates on coronary heart illness drug, COVID vaccine gross sales
(Reuters) -Drugmaker Pfizer beat Wall Avenue estimates for fourth-quarter revenue on Thursday, boosted by cost-cutting, a smaller-than-feared drop in gross sales of its COVID-19 vaccine and powerful demand for its coronary heart drug Vyndaqel. After the immense success of its COVID-19 merchandise throughout the pandemic, Pfizer has struggled to persuade shareholders that it could make … Read more